Business
Supernus to Participate in Upcoming September Investor Conferences
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and
About this update from Supernus Pharmaceuticals, Inc.
[{"type":"text","content":"ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate and host investor meetings in the following upcoming September 2021 virtual investor conferences. Citi’s 16th Annual BioPharma Virtual ConferenceDate: Thursday, September 9, 2021Participation Type: One-on-one meetings Wells Fargo 2021 Virtual Healthcare ConferenceDate: Friday, September 10, 2021Participation Type: PresentationPresentation Time: 9:20 a.m. ET Morgan Stanley 19th Annual Global Healthcare ConferenceDate: Wednesday, September 15, 2021Participation Type: Fireside ChatPresentation Time: 11:45 a.m. ET A live webcast of the events can be accessed by visiting Events & Presentations in the Investor Relations section on the Company's website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company's website after the respective conference. About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders. For more information, please visit www.supernus.com. CONTACTS: Jack A. Khattar, President and Chief Executive Officer Supernus Pharmaceuticals, Inc.Tel: (301) 838-2591 or INVESTOR CONTACT:Peter VozzoWestwicke/ICROffice: (443) 213-0505Mobile: (443) 377-4767Email: [email protected] \nSource: Supernus Pharmaceuticals, Inc.","length":4264,"tagName":"div"}]